The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
1,10-phenanthroline results in decreased activity of AHR protein [copper(II) nitrate binds to 1,10-phenanthroline binds to Quinolones] which results in increased activity of AHR protein; resveratrol inhibits the reaction [[copper(II) nitrate binds to 1,10-phenanthroline binds to Quinolones] which results in increased activity of AHR protein] 1,10-phenanthroline inhibits the reaction [Tetrachlorodibenzodioxin binds to AHR protein]; 1,10-phenanthroline inhibits the reaction [Tetrachlorodibenzodioxin promotes the reaction [AHR protein binds to CYP1A1 enhancer]]; Zinc inhibits the reaction [1,10-phenanthroline results in decreased activity of AHR protein]
1,10-phenanthroline results in decreased activity of ANPEP protein Edetic Acid promotes the reaction [1,10-phenanthroline results in decreased activity of ANPEP protein]
[1,10-phenanthroline results in decreased activity of MBTPS2 protein] which affects the localization of ATF6 protein; [1,10-phenanthroline results in decreased activity of MBTPS2 protein] which results in decreased cleavage of ATF6 protein
1,10-phenanthroline results in increased expression of CD86 mRNA Acetylcysteine inhibits the reaction [1,10-phenanthroline results in increased expression of CD86 mRNA]; SB 203580 inhibits the reaction [1,10-phenanthroline results in increased expression of CD86 mRNA]
1,10-phenanthroline inhibits the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 protein]; [1,10-phenanthroline co-treated with cupric chloride] inhibits the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 mRNA]; [1,10-phenanthroline co-treated with cupric chloride] inhibits the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 protein]; ferric chloride inhibits the reaction [1,10-phenanthroline inhibits the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 protein]]; zinc chloride inhibits the reaction [1,10-phenanthroline inhibits the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 protein]] [copper(II) nitrate binds to 1,10-phenanthroline binds to Quinolones] which results in increased expression of CYP1A1 mRNA 1,10-phenanthroline inhibits the reaction [Tetrachlorodibenzodioxin promotes the reaction [AHR protein binds to CYP1A1 enhancer]] 1,10-phenanthroline results in increased stability of CYP1A1 mRNA
4'-O-methylalpinumisoflavone inhibits the reaction [1,10-phenanthroline deficiency results in increased activity of HIF1A protein]; alpinumisoflavone inhibits the reaction [1,10-phenanthroline deficiency results in increased activity of HIF1A protein] HIF1A protein promotes the reaction [1,10-phenanthroline results in increased expression of VEGFA protein] 1,10-phenanthroline results in increased activity of HIF1A protein
1,10-phenanthroline inhibits the reaction [9,10-phenanthrenequinone results in decreased expression of HMOX1 protein]; 1,10-phenanthroline inhibits the reaction [Cadmium Chloride results in increased expression of HMOX1 mRNA]; 1,10-phenanthroline inhibits the reaction [Hydrogen Peroxide results in increased expression of HMOX1 mRNA]; 1,10-phenanthroline inhibits the reaction [Oxygen results in increased expression of HMOX1 mRNA]; 1,10-phenanthroline inhibits the reaction [Raloxifene Hydrochloride results in increased expression of HMOX1 mRNA]; 1,10-phenanthroline inhibits the reaction [sodium arsenite results in increased expression of HMOX1 mRNA]
[1,10-phenanthroline results in decreased activity of MBTPS2 protein] which affects the localization of ATF6 protein; [1,10-phenanthroline results in decreased activity of MBTPS2 protein] which affects the localization of SREBF1 protein; [1,10-phenanthroline results in decreased activity of MBTPS2 protein] which results in decreased cleavage of ATF6 protein; [1,10-phenanthroline results in decreased activity of MBTPS2 protein] which results in decreased cleavage of SREBF1 protein
1,10-phenanthroline inhibits the reaction [PLAU protein results in increased activity of MMP9 protein] 1,10-phenanthroline inhibits the reaction [Adenosine Triphosphate results in increased activity of MMP9 protein]
1,10-phenanthroline inhibits the reaction [9,10-phenanthrenequinone results in decreased expression of SOD1 protein]; 1,10-phenanthroline inhibits the reaction [[Hydrogen Peroxide co-treated with Nitroprusside] results in decreased expression of SOD1 protein]
[1,10-phenanthroline results in decreased activity of MBTPS2 protein] which affects the localization of SREBF1 protein; [1,10-phenanthroline results in decreased activity of MBTPS2 protein] which results in decreased cleavage of SREBF1 protein
1,10-phenanthroline results in increased expression of VEGFA mRNA; 1,10-phenanthroline results in increased expression of VEGFA protein HIF1A protein promotes the reaction [1,10-phenanthroline results in increased expression of VEGFA protein]
1,7-phenanthroline inhibits the reaction [Tetrachlorodibenzodioxin binds to AHR protein]; 1,7-phenanthroline inhibits the reaction [Tetrachlorodibenzodioxin promotes the reaction [AHR protein binds to CYP1A1 enhancer]]
1,7-phenanthroline results in increased expression of CYP1A1 protein 1,7-phenanthroline inhibits the reaction [[Dietary Fats co-treated with Dietary Sucrose] results in decreased expression of CYP1A1 protein]; 1,7-phenanthroline inhibits the reaction [Tetrachlorodibenzodioxin promotes the reaction [AHR protein binds to CYP1A1 enhancer]]
1,7-phenanthroline inhibits the reaction [[Dietary Fats co-treated with Dietary Sucrose] results in decreased expression of CYP1A2 protein] 1,7-phenanthroline results in increased expression of CYP1A2 protein
1,7-phenanthroline promotes the reaction [[Dietary Fats co-treated with Dietary Sucrose] results in increased expression of UGT1A6 protein] 1,7-phenanthroline results in increased expression of UGT1A6 protein
phenothiazine analog affects the localization of AR protein phenothiazine analog binds to and results in decreased activity of AR protein; phenothiazine inhibits the reaction [[6-fluorotestosterone co-treated with Norgestrel] binds to and results in increased activity of AR protein]
4,7-phenanthroline results in decreased activity of AHR protein 4,7-phenanthroline inhibits the reaction [AHR promotes the reaction [Tetrachlorodibenzodioxin results in decreased uptake of Glucose]] 4,7-phenanthroline inhibits the reaction [Tetrachlorodibenzodioxin binds to AHR protein]; 4,7-phenanthroline inhibits the reaction [Tetrachlorodibenzodioxin promotes the reaction [AHR protein binds to CYP1A1 enhancer]]
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of ACTB mRNA]
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of ATF4 mRNA]
ATOX1 protein affects the reaction [[bathocuproine sulfonate results in decreased abundance of Copper] which results in decreased expression of SLC31A2 mRNA]; ATOX1 protein affects the reaction [[bathocuproine sulfonate results in decreased abundance of Copper] which results in decreased expression of SLC31A2 protein]
[Penicillamine co-treated with bathocuproine sulfonate] promotes the reaction [CLU protein binds to ATP7A protein]; bathocuproine sulfonate inhibits the reaction [ATP7A protein results in increased activity of TYR protein]; cupric chloride inhibits the reaction [bathocuproine sulfonate inhibits the reaction [ATP7A protein results in increased activity of TYR protein]]
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of BCL2A1 mRNA]; bathocuproine sulfonate inhibits the reaction [pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of BCL2A1 mRNA]]
bathocuproine sulfonate inhibits the reaction [[Copper binds to neocuproine] which results in increased activity of CASP3 protein]; bathocuproine sulfonate inhibits the reaction [[Disulfiram binds to cupric chloride] which results in increased activity of CASP3 protein]; bathocuproine sulfonate inhibits the reaction [[pyrrolidine dithiocarbamic acid co-treated with Copper] results in increased activity of CASP3 protein]
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of CASP8 mRNA]; bathocuproine sulfonate inhibits the reaction [pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of CASP8 mRNA]]
bathocuproine sulfonate inhibits the reaction [pyrrolidine dithiocarbamic acid inhibits the reaction [TNF protein results in increased expression of CCL2 mRNA]]
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CCL3 mRNA]
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CCT5 mRNA]; bathocuproine sulfonate inhibits the reaction [pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CCT5 mRNA]]
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CD200 mRNA]
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CD44 mRNA]
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of CDH17 mRNA]; [pyrrolidine dithiocarbamic acid co-treated with bathocuproine sulfonate] results in increased expression of CDH17 mRNA
[Penicillamine co-treated with bathocuproine sulfonate] promotes the reaction [CLU protein binds to ATP7A protein]; [Penicillamine co-treated with bathocuproine sulfonate] promotes the reaction [CLU protein binds to ATP7B protein]
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of COMT mRNA]
bathocuproine sulfonate inhibits the reaction [pyrrolidine dithiocarbamic acid promotes the reaction [[JUN protein binds to FOS protein] which results in increased expression of and results in increased activity of CP protein]]; bathocuproine sulfonate inhibits the reaction [pyrrolidine dithiocarbamic acid results in increased expression of CP protein]
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CREM mRNA]
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of CUL5 mRNA]
bathocuproine sulfonate inhibits the reaction [pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of DUSP4 mRNA]]
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of EGR2 mRNA]
bathocuproine sulfonate inhibits the reaction [FGF2 protein results in increased phosphorylation of MAPK1 protein]; bathocuproine sulfonate inhibits the reaction [FGF2 protein results in increased phosphorylation of MAPK3 protein]
bathocuproine sulfonate inhibits the reaction [pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of FOS protein]]; bathocuproine sulfonate inhibits the reaction [pyrrolidine dithiocarbamic acid promotes the reaction [[JUN protein binds to FOS protein] which results in increased expression of and results in increased activity of CP protein]]
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of FYB1 mRNA]
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of GFRA2 mRNA]
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of HADHA mRNA]
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of HCK mRNA]
bathocuproine sulfonate inhibits the reaction [[cobaltiprotoporphyrin co-treated with HPX protein] affects the localization of MTF1 protein]; bathocuproine sulfonate inhibits the reaction [[cobaltiprotoporphyrin co-treated with HPX protein] results in increased expression of MTF1 mRNA]; bathocuproine sulfonate inhibits the reaction [[Heme co-treated with HPX protein] affects the localization of MTF1 protein]
[pyrrolidine dithiocarbamic acid co-treated with bathocuproine sulfonate] results in increased expression of HSPA8 mRNA; bathocuproine sulfonate inhibits the reaction [pyrrolidine dithiocarbamic acid promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of HSPA8 mRNA]]
bathocuproine sulfonate inhibits the reaction [pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 mRNA]]
bathocuproine sulfonate inhibits the reaction [di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2RA protein]]
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2RB mRNA]
bathocuproine sulfonate inhibits the reaction [pyrrolidine dithiocarbamic acid promotes the reaction [[JUN protein binds to FOS protein] which results in increased expression of and results in increased activity of CP protein]]; bathocuproine sulfonate inhibits the reaction [pyrrolidine dithiocarbamic acid promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of JUN protein]]
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of LCP1 mRNA]
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of LTBP4 mRNA]
bathocuproine sulfonate inhibits the reaction [pyrrolidine dithiocarbamic acid promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased phosphorylation of MAPK1 protein]] bathocuproine sulfonate inhibits the reaction [FGF2 protein results in increased phosphorylation of MAPK1 protein] bathocuproine sulfonate inhibits the reaction [pyrrolidine dithiocarbamic acid results in decreased activity of MAPK1 protein]
bathocuproine sulfonate inhibits the reaction [pyrrolidine dithiocarbamic acid promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased phosphorylation of MAPK3 protein]] bathocuproine sulfonate inhibits the reaction [FGF2 protein results in increased phosphorylation of MAPK3 protein] bathocuproine sulfonate inhibits the reaction [[pyrrolidine dithiocarbamic acid co-treated with Copper] results in increased activity of MAPK3 protein]
bathocuproine sulfonate inhibits the reaction [[Copper binds to neocuproine] which results in increased activity of MAPK8 protein]; bathocuproine sulfonate inhibits the reaction [[Disulfiram binds to cupric chloride] which results in increased activity of MAPK8 protein]; bathocuproine sulfonate inhibits the reaction [[pyrrolidine dithiocarbamic acid co-treated with Copper] results in increased activity of MAPK8 protein]
bathocuproine sulfonate inhibits the reaction [[cobaltiprotoporphyrin co-treated with HPX protein] affects the localization of MTF1 protein]; bathocuproine sulfonate inhibits the reaction [[cobaltiprotoporphyrin co-treated with HPX protein] results in increased expression of MTF1 mRNA]; bathocuproine sulfonate inhibits the reaction [[Heme co-treated with HPX protein] affects the localization of MTF1 protein]
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of MYC mRNA]
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of NAA80 mRNA]
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of NELL1 mRNA]
bathocuproine sulfonate inhibits the reaction [pyrrolidine dithiocarbamic acid inhibits the reaction [TNF protein results in increased activity of NFKB1 protein]]
bathocuproine sulfonate inhibits the reaction [pyrrolidine dithiocarbamic acid inhibits the reaction [TNF protein results in increased degradation of NFKBIA protein]]
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of NMI mRNA]
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of NR4A3 mRNA]
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of REL mRNA]
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of SLA mRNA]
[bathocuproine sulfonate results in decreased abundance of Copper] which results in increased expression of SLC31A1 mRNA; bathocuproine sulfonate promotes the reaction [SP1 protein results in increased expression of SLC31A1 mRNA]
[[bathocuproine sulfonate results in decreased abundance of Copper] which results in decreased expression of SLC31A2 protein] which results in increased uptake of and results in increased susceptibility to Cisplatin; [bathocuproine sulfonate results in decreased abundance of Copper] which results in decreased expression of SLC31A2 protein bathocuproine sulfonate affects the localization of SLC31A2 protein ATOX1 protein affects the reaction [[bathocuproine sulfonate results in decreased abundance of Copper] which results in decreased expression of SLC31A2 mRNA]; ATOX1 protein affects the reaction [[bathocuproine sulfonate results in decreased abundance of Copper] which results in decreased expression of SLC31A2 protein]
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of SRPRA mRNA]
bathocuproine sulfonate inhibits the reaction [pyrrolidine dithiocarbamic acid inhibits the reaction [TNF protein results in increased activity of NFKB1 protein]]; bathocuproine sulfonate inhibits the reaction [pyrrolidine dithiocarbamic acid inhibits the reaction [TNF protein results in increased degradation of NFKBIA protein]]; bathocuproine sulfonate inhibits the reaction [pyrrolidine dithiocarbamic acid inhibits the reaction [TNF protein results in increased expression of CCL2 mRNA]]
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of TNFRSF1B mRNA]
bathocuproine sulfonate inhibits the reaction [[pyrrolidine dithiocarbamic acid results in increased abundance of Copper] which results in increased oxidation of and results in increased expression of TP53 protein]
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TRAF1 mRNA]; bathocuproine sulfonate inhibits the reaction [pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TRAF1 mRNA]]
bathocuproine sulfonate inhibits the reaction [ATP7A protein results in increased activity of TYR protein]; cupric chloride inhibits the reaction [bathocuproine sulfonate inhibits the reaction [ATP7A protein results in increased activity of TYR protein]]
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of TYROBP mRNA]
[bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of VIM mRNA]
norharman inhibits the reaction [Lipids metabolite results in increased activity of AHR protein] norharman results in increased activity of AHR protein
CYP1A1 protein affects the metabolism of [norharman co-treated with aniline] norharman results in increased expression of CYP1A1 mRNA; norharman results in increased expression of CYP1A1 protein
norharman inhibits the reaction [MAOB protein results in increased oxidation of 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] norharman results in decreased activity of MAOB protein
norharman results in decreased activity of SLC22A1 protein norharman inhibits the reaction [SLC22A1 protein results in increased import of 4-(4-(dimethylamino)styryl)-1-methylpyridinium iodide]
norharman results in decreased activity of SLC22A2 protein norharman inhibits the reaction [SLC22A2 protein results in increased import of 4-(4-(dimethylamino)styryl)-1-methylpyridinium iodide]
norharman results in decreased activity of SLC22A3 protein norharman inhibits the reaction [SLC22A3 protein results in increased import of 4-(4-(dimethylamino)styryl)-1-methylpyridinium iodide]
Clomipramine results in increased cleavage of and results in increased activity of CASP3 protein; Palmitic Acid promotes the reaction [Clomipramine results in increased activity of CASP3 protein]
Clomipramine results in increased activity of and results in increased secretion of GPT protein Clomipramine results in increased export of GPT protein
[IL6 protein co-treated with IL1A protein co-treated with TNF protein co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased susceptibility to Clomipramine
[IL6 protein co-treated with IL1A protein co-treated with TNF protein co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased susceptibility to Clomipramine
Clomipramine affects the secretion of PRL protein Clomipramine results in increased expression of PRL protein SLC6A4 polymorphism inhibits the reaction [Clomipramine affects the secretion of PRL protein] Clomipramine results in increased secretion of PRL protein
Clomipramine binds to and results in decreased activity of SLC6A4 protein; SLC6A4 polymorphism inhibits the reaction [Clomipramine affects the secretion of PRL protein]
[IL6 protein co-treated with IL1A protein co-treated with TNF protein co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased susceptibility to Clomipramine
AHR protein promotes the reaction [dibenzofuran analog results in increased expression of CDKN1A mRNA]; AHR protein promotes the reaction [dibenzofuran analog results in increased expression of CDKN1B mRNA]; AHR protein promotes the reaction [dibenzofuran analog results in increased expression of GSTA2 mRNA]; AHR protein promotes the reaction [dibenzofuran analog results in increased expression of PLA2G2A mRNA]; AHR protein promotes the reaction [dibenzofuran analog results in increased expression of PTGS2 mRNA]; dibenzofuran binds to and results in increased activity of AHR protein dibenzofuran analog results in increased activity of AHR protein dibenzofuran analog affects the localization of AHR protein
dibenzofuran analog results in increased expression of CDKN1A mRNA AHR protein promotes the reaction [dibenzofuran analog results in increased expression of CDKN1A mRNA]
dibenzofuran analog results in increased expression of CDKN1B mRNA; dibenzofuran analog results in increased expression of CDKN1B protein AHR protein promotes the reaction [dibenzofuran analog results in increased expression of CDKN1B mRNA]
2,2',4,4',5-brominated diphenyl ether inhibits the reaction [dibenzofuran analog results in increased expression of CYP1A1 mRNA]; 2,2',4,4'-tetrabromodiphenyl ether inhibits the reaction [dibenzofuran analog results in increased expression of CYP1A1 mRNA]; 2,2',4,4'-tetrabromodiphenyl ether inhibits the reaction [dibenzofuran analog results in increased expression of CYP1A1 protein] dibenzofuran analog results in increased expression of CYP1A1 mRNA; dibenzofuran analog results in increased expression of CYP1A1 protein
dibenzofuran results in increased activity of CYP1A2 protein dibenzofuran metabolite results in increased activity of CYP1A2 protein [acenaphthylene co-treated with acenaphthene co-treated with dibenzofuran co-treated with fluorene co-treated with phenanthrene co-treated with anthracene] results in increased expression of CYP1A2 mRNA
dibenzofuran analog results in increased expression of PTGS2 mRNA AHR protein promotes the reaction [dibenzofuran analog results in increased expression of PTGS2 mRNA]
[Pyruvic Acid co-treated with Uridine co-treated with Ethidium] inhibits the reaction [Rotenone inhibits the reaction [arsenite results in increased expression of ERO1A protein]]
Ethidium inhibits the reaction [sodium arsenate results in increased expression of IL1A protein]; Ethidium inhibits the reaction [tributyltin results in increased expression of IL1A protein]
1-Methyl-4-phenylpyridinium inhibits the reaction [SLC22A1 protein results in increased uptake of Ethidium]; Cimetidine inhibits the reaction [SLC22A1 protein results in increased uptake of Ethidium]; Quinine inhibits the reaction [SLC22A1 protein results in increased uptake of Ethidium]; Tetraethylammonium inhibits the reaction [SLC22A1 protein results in increased uptake of Ethidium] SLC22A1 protein affects the uptake of Ethidium
SLC22A2 protein affects the uptake of Ethidium 1-Methyl-4-phenylpyridinium inhibits the reaction [SLC22A2 protein results in increased uptake of Ethidium]; Cimetidine inhibits the reaction [SLC22A2 protein results in increased uptake of Ethidium]; Ethidium inhibits the reaction [SLC22A2 protein results in increased uptake of 1-Methyl-4-phenylpyridinium]; Quinine inhibits the reaction [SLC22A2 protein results in increased uptake of Ethidium]; Tetraethylammonium inhibits the reaction [SLC22A2 protein results in increased uptake of Ethidium]
SLC22A3 protein results in increased uptake of Ethidium 1-Methyl-4-phenylpyridinium inhibits the reaction [SLC22A3 protein results in increased uptake of Ethidium]; Cimetidine inhibits the reaction [SLC22A3 protein results in increased uptake of Ethidium]; Quinine inhibits the reaction [SLC22A3 protein results in increased uptake of Ethidium]; Tetraethylammonium inhibits the reaction [SLC22A3 protein results in increased uptake of Ethidium]
[Fluphenazine co-treated with diphenyldiselenide] results in decreased activity of ALAD protein Fluphenazine results in decreased activity of ALAD protein
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [harmol results in decreased stability of CYP1A1 protein]; harmol inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]; harmol inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 protein] harmol results in decreased activity of CYP1A1 protein
Imipramine inhibits the reaction [asoxime chloride inhibits the reaction [cyclohexyl methylphosphonofluoridate results in decreased activity of ACHE protein]]; Imipramine inhibits the reaction [asoxime chloride inhibits the reaction [Sarin results in decreased activity of ACHE protein]]; Imipramine inhibits the reaction [Obidoxime Chloride metabolite results in decreased activity of ACHE protein]; Imipramine promotes the reaction [Obidoxime Chloride inhibits the reaction [Sarin results in decreased activity of ACHE protein]] Imipramine results in increased activity of ACHE protein Imipramine results in decreased activity of ACHE protein
[Imipramine co-treated with Idazoxan] results in decreased activity of ADRB1 protein; [Imipramine co-treated with Yohimbine] results in decreased activity of ADRB1 protein Imipramine results in decreased activity of ADRB1 protein
Imipramine affects the reaction [caryophyllene inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of ARG1 protein]]
Imipramine results in increased expression of BDNF mRNA Rolipram promotes the reaction [Imipramine results in increased expression of BDNF mRNA] Imipramine affects the expression of BDNF protein
Imipramine results in increased cleavage of and results in increased activity of CASP3 protein; Palmitic Acid promotes the reaction [Imipramine results in increased activity of CASP3 protein]
Imipramine results in increased activity of CASP7 protein Palmitic Acid promotes the reaction [Imipramine results in increased activity of CASP7 protein]
Imipramine results in increased expression of CREB1 mRNA Imipramine results in increased phosphorylation of CREB1 protein Rolipram promotes the reaction [Imipramine results in increased expression of CREB1 mRNA]
CYP1A2 protein affects the metabolism of Imipramine CYP1A2 protein results in increased metabolism of Imipramine CYP1A2 protein results in decreased methylation of and results in increased activity of Imipramine; Imipramine inhibits the reaction [resveratrol results in decreased activity of CYP1A2 protein]; Organophosphorus Compounds inhibits the reaction [CYP1A2 protein results in decreased methylation of and results in increased activity of Imipramine]
CYP2C19 protein affects the metabolism of Imipramine CYP2C19 protein results in decreased methylation of and results in increased activity of Imipramine; Organophosphorus Compounds inhibits the reaction [CYP2C19 protein results in decreased methylation of and results in increased activity of Imipramine]
CYP3A4 protein results in decreased methylation of and results in increased activity of Imipramine; Organophosphorus Compounds inhibits the reaction [CYP3A4 protein results in decreased methylation of and results in increased activity of Imipramine]
Imipramine results in increased expression of HSPA8 mRNA alternative form; Imipramine results in increased expression of HSPA8 protein alternative form
Imipramine affects the reaction [caryophyllene promotes the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of IL10 protein]]
Imipramine affects the reaction [caryophyllene inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of IL1B protein]]; Imipramine inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of IL1B protein]
Imipramine binds to and results in decreased activity of KCNH2 protein; Imipramine inhibits the reaction [KCNH2 protein results in increased transport of Thallium] Imipramine results in decreased activity of KCNH2 protein Imipramine results in decreased localization of KCNH2 protein
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Imipramine binds to and results in increased activity of MAPK1 protein]; Imipramine binds to and results in increased activity of MAPK1 protein
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Imipramine binds to and results in increased activity of MAPK3 protein]; Imipramine binds to and results in increased activity of MAPK3 protein
Imipramine inhibits the reaction [NTRK2 protein binds to AP2M1 protein]; Imipramine promotes the reaction [NTRK2 protein binds to PLCG1 protein modified form]; Imipramine results in increased phosphorylation of and results in increased activity of NTRK2 protein Imipramine results in increased phosphorylation of NTRK2 protein
Imipramine inhibits the reaction [SLC22A1 protein results in increased uptake of Metformin]; Imipramine inhibits the reaction [SLC22A1 protein results in increased uptake of Quercetin]; Imipramine inhibits the reaction [SLC22A1 protein results in increased uptake of Tetraethylammonium]
Imipramine inhibits the reaction [SLC22A2 protein polymorphism results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium]; Imipramine inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium]
Imipramine inhibits the reaction [SLC22A3 protein results in increased uptake of 1-Methyl-4-phenylpyridinium analog]; Imipramine inhibits the reaction [SLC22A3 protein results in increased uptake of 1-Methyl-4-phenylpyridinium]; Imipramine inhibits the reaction [SLC22A3 protein results in increased uptake of Metformin]
Imipramine results in decreased activity of SLC47A1 protein Imipramine inhibits the reaction [SLC47A1 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium]
Imipramine affects the reaction [caryophyllene inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of TNF protein]]; Imipramine inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of TNF protein]; Imipramine inhibits the reaction [TNF protein results in increased abundance of N-palmitoylsphingosine] Imipramine inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of TNF protein]; Imipramine promotes the reaction [caryophyllene inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of TNF protein]]
Finasteride inhibits the reaction [UGT1A4 protein results in increased glucuronidation of Imipramine] UGT1A4 protein results in increased glucuronidation of Imipramine; UGT1A4 protein SNP results in increased glucuronidation of Imipramine UGT1A4 protein affects the metabolism of Imipramine
Perphenazine inhibits the reaction [CES1 protein results in increased hydrolysis of 4-nitrophenyl acetate]; Perphenazine inhibits the reaction [CES1 protein results in increased hydrolysis of Methylphenidate]
Perphenazine inhibits the reaction [KCNH2 protein results in increased transport of Thallium] Perphenazine results in decreased activity of KCNH2 protein
ABCB1 protein results in increased transport of Quinacrine Elacridar inhibits the reaction [ABCB1 protein results in increased transport of Quinacrine]
BAX protein results in increased susceptibility to Quinacrine Quinacrine results in increased expression of BAX mRNA 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Quinacrine results in increased expression of BAX mRNA]; 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Quinacrine results in increased expression of BAX protein]; BTRC protein inhibits the reaction [Quinacrine results in increased expression of BAX protein]; mithramycin A inhibits the reaction [Quinacrine results in increased expression of BAX mRNA]; mithramycin A inhibits the reaction [Quinacrine results in increased expression of BAX protein]; Quinacrine promotes the reaction [SP1 protein binds to BAX promoter]; Quinacrine results in increased expression of and affects the localization of BAX protein
Quinacrine results in decreased expression of BTRC protein 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Quinacrine results in decreased expression of BTRC protein]; BTRC protein inhibits the reaction [Quinacrine results in increased expression of BAX protein]; BTRC protein inhibits the reaction [Quinacrine results in increased expression of SP1 protein]; FOXP3 protein affects the reaction [Quinacrine results in decreased expression of BTRC protein]; MIR183 mRNA affects the reaction [Quinacrine results in decreased expression of BTRC protein]; Quinacrine results in decreased expression of and results in decreased stability of BTRC mRNA
Quinacrine results in increased cleavage of CASP3 protein GSK3B protein affects the reaction [Quinacrine results in increased activity of CASP3 protein]
Quinacrine results in decreased expression of CCND1 protein GSK3B protein affects the reaction [Quinacrine results in decreased expression of CCND1 protein]
Quinacrine results in increased expression of CSNK1A1 protein GSK3B protein affects the reaction [Quinacrine results in increased expression of CSNK1A1 protein]
Quinacrine results in increased expression of FOXP3 mRNA; Quinacrine results in increased expression of FOXP3 protein 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Quinacrine results in increased expression of FOXP3 mRNA]; 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Quinacrine results in increased expression of FOXP3 protein]; FOXP3 protein affects the reaction [Quinacrine results in decreased expression of BTRC protein]; FOXP3 protein affects the reaction [Quinacrine results in increased expression of MIR183 mRNA]; FOXP3 protein affects the reaction [Quinacrine results in increased expression of SP1 protein]
Quinacrine results in decreased expression of GLI1 protein GSK3B protein affects the reaction [Quinacrine results in decreased expression of GLI1 protein]
Quinacrine results in increased expression of GSK3B mRNA GSK3B protein affects the reaction [Quinacrine results in decreased expression of CCND1 protein]; GSK3B protein affects the reaction [Quinacrine results in decreased expression of CTNNB1 protein]; GSK3B protein affects the reaction [Quinacrine results in decreased expression of GLI1 protein]; GSK3B protein affects the reaction [Quinacrine results in decreased expression of MYC protein]; GSK3B protein affects the reaction [Quinacrine results in increased activity of CASP3 protein]; GSK3B protein affects the reaction [Quinacrine results in increased expression of CSNK1A1 protein]; Quinacrine results in increased expression of and results in decreased phosphorylation of GSK3B protein
Quinacrine results in decreased phosphorylation of MAPK1 protein 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Quinacrine results in decreased phosphorylation of MAPK1 protein]; Acetylcysteine inhibits the reaction [Quinacrine results in decreased phosphorylation of MAPK1 protein]
Quinacrine results in decreased phosphorylation of MAPK3 protein 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Quinacrine results in decreased phosphorylation of MAPK3 protein]; Acetylcysteine inhibits the reaction [Quinacrine results in decreased phosphorylation of MAPK3 protein]
FOXP3 protein affects the reaction [Quinacrine results in increased expression of MIR183 mRNA]; MIR183 mRNA affects the reaction [Quinacrine results in decreased expression of BTRC protein]; MIR183 mRNA affects the reaction [Quinacrine results in increased expression of SP1 protein]
Quinacrine results in decreased expression of MYC protein GSK3B protein affects the reaction [Quinacrine results in decreased expression of MYC protein]
Quinacrine inhibits the reaction [PRL protein results in increased activity of OTC protein]; Quinacrine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased activity of OTC protein]
4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Quinacrine results in increased expression of SP1 protein]; BTRC protein inhibits the reaction [Quinacrine results in increased expression of SP1 protein]; FOXP3 protein affects the reaction [Quinacrine results in increased expression of SP1 protein]; MIR183 mRNA affects the reaction [Quinacrine results in increased expression of SP1 protein]; Quinacrine promotes the reaction [SP1 protein binds to BAX promoter]; Quinacrine results in increased expression of and results in increased stability of SP1 protein
Quinacrine results in increased activity of TP53 protein Quinacrine affects the activity of TP53 protein Quinacrine results in increased stability of and results in increased activity of TP53 protein
browse the term
